Brought to you by 
Yale University grants Biohaven exclusive IP rights
22 Feb 2018
Executive Summary
Yale University granted Biohaven Pharmaceuticals Holding Co. Ltd. an exclusive license to its intellectual property surrounding the use of glutamate-modulating agents, including riluzole, which the company will use in its development of therapeutics for neuropsychiatric conditions, including treatment-resistant mood and anxiety disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Yale University grants Biohaven exclusive IP rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice